Abstract

The current study aimed to evaluate the beneficial effect of kefir probiotic and /or Mesenchymal stem cells (MSCs) on acute kidney injury (AKI) induced by lipopolysaccharide (LPS) challenge, and to investigate could kefir potentiate the therapeutic action of MSCs. Sixty female albino rats were used in this study and divided into 6 groups (10 rats each): control group; LPS-challenged group; LPS + MSCs group; LPS + kefir group; kefir +LPS +kefir (prophylactic) group and kefir + LPS + MSCs + kefir (prophylactic-MSCs) group. Samples were collected at two point's time. Renal function, serum IL-10, TNF-α, renal MDA, GSH contents, SOD and PON-I were assayed. The mRNA expression of NF-κB, iNOS and caspase-3 were monitored in kidney tissue. Our results revealed that LPS significantly increased renal function tests, TNF-α in association with dramatic decrease of creatinine clearance and serum IL-10 levels. Oxidative stress was proved in LPS group by increasing MDA level, reduction in GSH content, SOD and PON-1 activities in kidney. The mRNA expression of NF-κB, iNOS and caspase-3 were significantly up-regulated in AKI. Administration of kefir or MSCs alone significantly attenuated LPS-induced AKI. The pre and co-treatment of kefir with MSCs potentiate their therapeutic action. Conclusion: A combination of kefir probiotic and MSCs may be of interest for clinical use.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call